February 20, 2018
US Bioservices now dispenses ERLEADA
The U.S. Food and Drug Administration has approved ERLEADA (apalutamide) for non-metastatic castration-resistant prostate cancer.
The U.S. Food and Drug Administration has approved ERLEADA (apalutamide) for non-metastatic castration-resistant prostate cancer.